New Report on Drugs for Drug-resistant TB

The Médecins Sans Frontières and The Union will release on World TB Day a new report entitled “DR-TB drugs under the microscope” outlining drugs currently available to treat drug-resistant tuberculosis (DR-TB) including product information, sources of the drug, quality status, and price. The purpose of the report is to act as an aid to treatment providers, treatment programs, and national procurement centers in making decisions about which drugs to purchase and implement.

The report groups available TB drugs into five categories: 1) first-line oral agents 2) injectable agents 3) fluoroquinolones 4) Oral bacteriostatic second-line agents 5) Agents with unclear efficacy. The focus of the report is to detail the information on the drugs in groups 2 through 5.

In addition, the report presents an overview of the market and looks at challenges that are present when addressing DR-TB such as limited number of quality sources, affordability, and neglect of children and people living with HIV/AIDS. The report aims to provide quality information and to be transparent regarding pricing of these drugs.

The online Global TB Drug Pipeline available on the WGND website is cited in the report (see page 11 and 45).

Click here to read full report.

More News
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...
3 Aug 2023
The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
23 Aug 2022
The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...